Thermon Group (THR) delivered earnings and revenue surprises of 8.57% and 1.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?